Seattle Genetics Announces Data from Investigator-Sponsored Trials of ADCETRIS® (Brentuximab Vedotin) in Cutaneous T-Cell Lymphoma at ASH Annual Meeting
18:15 EST 10 Dec 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that results from
two ongoing investigator-sponsored phase II clinical trials of ADCETRIS
(brentuximab vedotin) in patients with relapsed cutaneous T-cell
lymphoma (CTCL) wer...
Other Sources for this Article
Seattle Genetics, Inc.
Investors:
Peggy Pinkston
+1-425-527-4160
ppinkston@seagen.com
or
Media:
Tricia
Larson
+1-425-527-4180
tlarson@seagen.com
More From BioPortfolio on "Seattle Genetics Announces Data from Investigator-Sponsored Trials of ADCETRIS® (Brentuximab Vedotin) in Cutaneous T-Cell Lymphoma at ASH Annual Meeting"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
